PeptidePedia The community reference

Contributions of AnalyticalAnnie

User contributions·143 logged edits·page 1 of 2

Contributions by AnalyticalAnnie, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 37,940 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 11,379 +1,295 add the registered legal name exactly as it appears in the registry record
  2. 14:49, 20 Jul 2026 (diff | hist) Sarcopenia 4,491 ±0 m fix the anchor on an internal link
  3. 20:07, 17 Jul 2026 (diff | hist) Gastric emptying 5,565 ±0 expand §Interaction with oral drugs
  4. 13:49, 17 Jul 2026 (diff | hist) Multi-dose vial 24,688 ±0 m rm the titration schedule — that belongs on the compound article
  5. 22:13, 15 Jul 2026 (diff | hist) Customs seizure 4,785 ±0 m add the citation for the regulatory action
  6. 08:17, 24 Jun 2026 (diff | hist) Purity claim inflation 5,660 ±0 de-duplicate a repeated sentence
  7. 13:33, 20 Jun 2026 (diff | hist) Sarcopenia 4,491 ±0 add the note that a single value out of range is not a finding
  8. 09:53, 18 Jun 2026 (diff | hist) Lot traceability 5,317 ±0 expand §What a lot is
  9. 17:47, 17 Jun 2026 (diff | hist) Active pharmaceutical ingredient 4,569 ±0 space between number and unit per PP:MOS
  10. 12:01, 4 Jun 2026 (diff | hist) Shanghai Wibson Biotechnology 15,440 ±0 rm the discount code added by an anonymous editor
  11. 07:45, 26 May 2026 (diff | hist) Underfilling 4,882 ±0 ce
  12. 11:12, 22 May 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 consistent en dashes in ranges
  13. 01:29, 15 May 2026 (diff | hist) Placebo-adjusted effect 4,805 ±0 name the funder in the sentence, per PP:MOS
  14. 16:18, 14 May 2026 (diff | hist) SURPASS trial programme 5,078 ±0 add the trial acronym expansion at first use
  15. 10:25, 7 May 2026 (diff | hist) Talk:MOTS-c 537 +148 /* Assay comparability */ new section
  16. 11:07, 19 Apr 2026 (diff | hist) Talk:Proglucagon 537 +122 /* Assay cross-reactivity deserves its own article */ new section
  17. 06:12, 19 Apr 2026 (diff | hist) Cagrilintide 4,256 ±0 expand §Reported findings
  18. 02:27, 19 Apr 2026 (diff | hist) Shanghai Wibson Biotechnology 15,440 ±0 ce
  19. 12:31, 18 Apr 2026 (diff | hist) Talk:Karl Fischer titration 1,022 +178 /* Should the mass-balance table give ranges or single figures? */ reply
  20. 15:44, 15 Apr 2026 (diff | hist) Talk:Peptide stability table 885 +304 /* RfC: should the table give a −20 °C default for research powders? */ reply
  21. 12:33, 8 Apr 2026 (diff | hist) Talk:Incretin effect 811 +236 /* Measurement methods: mention the glucagon secretion measurement too? */ new section
  22. 12:09, 29 Mar 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 typo
  23. 13:15, 26 Mar 2026 (diff | hist) Talk:Incretin effect 748 +258 /* Asymmetric loss in T2D — is the GIP figure sourced? */ reply
  24. 16:39, 24 Mar 2026 (diff | hist) Certificate of analysis 10,014 ±0 add the note that self-submitted reports are a self-selected sample
  25. 11:05, 19 Mar 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 537 +244 /* Adipose-tissue mechanism remains speculative */ new section
  26. 16:29, 2 Mar 2026 (diff | hist) Fmoc chemistry 4,618 ±0 clarify that the cake appearance is an indicator, not a specification
  27. 22:12, 18 Feb 2026 (diff | hist) Cost per milligram 4,125 ±0 m rm the projection; nothing cited supports it
  28. 22:19, 16 Feb 2026 (diff | hist) MOTS-c 4,670 ±0 add category for the peptide class
  29. 13:15, 16 Feb 2026 (diff | hist) Talk:Analytical method validation 611 +138 /* Stability-indicating claims */ reply
  30. 09:22, 7 Feb 2026 (diff | hist) Residual solvent 5,085 ±0 state that ultraviolet response is not uniform across impurities
  31. 13:15, 6 Feb 2026 (diff | hist) Talk:Gastric emptying 611 +121 /* Method comparability */ reply
  32. 00:18, 4 Feb 2026 (diff | hist) Janoshik Analytical 5,235 ±0 convert the service comparison to a table
  33. 10:15, 30 Jan 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 537 +197 /* Assay caveat should be more prominent */ new section
  34. 10:33, 28 Jan 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 1,022 +190 /* Fasting concentration range — should this be in the infobox? */ reply
  35. 22:49, 27 Jan 2026 (diff | hist) WuXi TIDES 16,434 ±0 add the minimum order quantity for custom synthesis
  36. 04:22, 25 Jan 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 expand §Physiology
  37. 13:18, 24 Jan 2026 (diff | hist) Albumin binding half-life extension 6,399 ±0 add a figure for the secretion time course and caption it
  38. 13:05, 22 Jan 2026 (diff | hist) Talk:Enteroendocrine L cell 811 +208 /* Should this article cover L-cell-derived peptides beyond GLP-1? */ new section
  39. 13:25, 5 Jan 2026 (diff | hist) Shanghai Wibson Biotechnology 15,440 ±0 add the how-to-request-a-batch-record sentence to §Ordering and availability
  40. 08:42, 3 Jan 2026 (diff | hist) Retatrutide 7,421 ±0 add the excipient list from the labelling
  41. 13:29, 27 Dec 2025 (diff | hist) High-performance liquid chromatography 7,231 ±0 rm the vendor name from a methodological sentence
  42. 01:22, 22 Dec 2025 (diff | hist) Amino acid analysis 4,943 ±0 add the repeatability figure with the number of injections
  43. 14:30, 21 Dec 2025 (diff | hist) Mass spectrometry 5,612 ±0 m state the titration endpoint and the reagent factor
  44. 04:14, 14 Dec 2025 (diff | hist) Grey market 4,279 ±0 m convert the storage conditions to a table
  45. 11:45, 13 Dec 2025 (diff | hist) Dose escalation schedule 4,993 ±0 m add the beyond-use interval with the storage condition it assumes
  46. 10:20, 9 Dec 2025 (diff | hist) Bacterial endotoxin test 5,317 ±0 fix indentation in the source
  47. 15:08, 4 Dec 2025 (diff | hist) Talk:Temperature excursion 885 +352 /* Is a community-reported stability observation usable evidence at all? */ reply
  48. 18:06, 3 Dec 2025 (diff | hist) Active pharmaceutical ingredient 4,569 ±0 rm the claim that the position has changed; no source supports it
  49. 12:59, 22 Nov 2025 (diff | hist) Semaglutide 10,355 ±0 m add the molecular formula to the infobox
  50. 09:24, 22 Nov 2025 (diff | hist) Cost per milligram 4,125 ±0 m ce per PP:MOS
  51. 16:45, 19 Nov 2025 (diff | hist) Grey market 4,279 +211 attribute the stability figure to the study and its duration
  52. 10:15, 12 Nov 2025 (diff | hist) AmbioPharm 7,763 +946 clarify that a registered business scope is a licensing fact, not a quality assurance
  53. 13:57, 7 Nov 2025 (diff | hist) PolyPeptide Group (Hangzhou) 9,618 +1,150 expand §Distribution and dispatch
  54. 13:53, 6 Nov 2025 (diff | hist) Amylin 5,795 ±0 m split overlong sentence
  55. 02:50, 2 Nov 2025 (diff | hist) WuXi TIDES 16,214 ±0 m attribute the documentation description to the purchaser reports it comes from
  56. 15:41, 8 Oct 2025 (diff | hist) Talk:Chinese Peptide Company 748 +314 /* The water-figure observation — are we praising a supplier? */ reply
  57. 09:55, 21 Sep 2025 (diff | hist) Talk:Lyophilisation 1,096 +214 /* Collapse temperature and Tg-prime are being used interchangeably */ reply
  58. 21:45, 9 Sep 2025 (diff | hist) Sterile water for injection 4,738 ±0 add the note about drawing air before withdrawal
  59. 09:21, 9 Sep 2025 (diff | hist) Talk:Peptide stability table 822 +303 /* Sourcing of the reconstituted-stability column */ reply
  60. 17:09, 7 Sep 2025 (diff | hist) Peptide stability table 5,688 ±0 m de-duplicate a repeated sentence
  61. 22:37, 27 Aug 2025 (diff | hist) Reference standard 5,217 ±0 m copyedit
  62. 15:29, 26 Aug 2025 (diff | hist) Reverse-phase HPLC 5,499 ±0 rm the claim that the method is stability-indicating without a forced-degradation study
  63. 11:38, 14 Aug 2025 (diff | hist) Talk:Karl Fischer titration 611 +327 /* Worked example — is the arithmetic order right? */ reply
  64. 22:35, 13 Aug 2025 (diff | hist) USP General Chapter 85 4,920 +625 m clarify that mass spectrometry confirms identity, not purity
  65. 12:18, 12 Aug 2025 (diff | hist) Peptide synthesis 4,967 ±0 add the crimp-seal step to the fill-and-finish description
  66. 10:29, 23 Jul 2025 (diff | hist) Shanghai ERP Biotechnology 3,790 +696 add the outbound storefront link, marked nofollow and sponsored per the external-links convention
  67. 09:28, 23 Jul 2025 (diff | hist) Talk:Cold chain 1,096 +264 /* Logger accuracy: is ±0.5 °C a standard or an expectation? */ reply
  68. 20:10, 18 Jul 2025 (diff | hist) Chain of custody 5,022 +314 split §What a report shows from §What it does not
  69. 12:19, 17 Jul 2025 (diff | hist) Amylin 5,099 +650 m state which salt form the mass in the infobox refers to
  70. 08:39, 16 Jul 2025 (diff | hist) Talk:Nantong Guangyuan Chemical 959 +166 /* The warehouse interval is a fact a purchaser can ask for */ reply
  71. 14:14, 13 Jul 2025 (diff | hist) Area percent purity 7,380 +616 m correct the resolution formula — the denominator is the sum of the widths
  72. 22:22, 1 Jul 2025 (diff | hist) Prescribing information 4,364 ±0 m fix indentation in the source
  73. 13:37, 28 Jun 2025 (diff | hist) ISO 9001 3,898 +519 add the note that this wiki does not give legal advice
  74. 09:41, 24 Jun 2025 (diff | hist) Talk:Hunan Aslsen Technology 537 +314 /* Area percent on non-peptide lines */ new section
  75. 11:24, 22 Jun 2025 (diff | hist) Insulin secretion 6,373 ±0 m expand §Failure in type 2 diabetes
  76. 13:42, 17 Jun 2025 (diff | hist) Limit of detection 4,001 ±0 m correct the flow rate — the source gives it in mL/min
  77. 10:02, 11 Jun 2025 (diff | hist) Talk:Glucagon-like peptide-1 1,159 +247 /* Should the fasting concentration range be in the infobox? */ reply
  78. 14:22, 10 Jun 2025 (diff | hist) Talk:Zhuhai Kerui Biotechnology 611 +445 /* Method disclosure: are we writing an endorsement? */ reply
  79. 21:08, 6 Jun 2025 (diff | hist) Contract development and manufacturing organisation 4,216 ±0 add the cross-link to the temperature-excursion article
  80. 02:52, 26 May 2025 (diff | hist) Cost per milligram 3,292 +170 m expand §Other axes that a price hides
  81. 09:24, 23 May 2025 (diff | hist) Peptide harm reduction 3,975 ±0 split §Pricing from §Coverage
  82. 00:40, 22 May 2025 (diff | hist) Hunan Aslsen Technology 10,064 ±0 m expand §Reception
  83. 13:44, 20 May 2025 (diff | hist) Talk:Guangzhou JEEP Biotechnology 748 +260 /* Method disclosure within one report set */ reply
  84. 20:05, 19 May 2025 (diff | hist) Batch number 3,731 ±0 add the laboratory accreditation status, or say plainly that it is not stated
  85. 08:31, 16 May 2025 (diff | hist) Talk:Reconstitution calculator 1,170 +90 /* Should the default vial mass be the gross or net figure? */ reply
  86. 13:22, 14 May 2025 (diff | hist) Talk:Reconstitution calculator 537 +429 /* Should the default vial mass be the gross or net figure? */ new section
  87. 08:33, 8 May 2025 (diff | hist) Talk:Shanghai ERP Biotechnology 959 +296 /* Endotoxin results: worth a paragraph? */ reply
  88. 13:58, 6 May 2025 (diff | hist) Talk:Area percent purity 885 +210 /* Should the four unseen categories be a definition list? */ reply
  89. 00:08, 26 Apr 2025 (diff | hist) Prior authorisation 3,226 +132 expand §How it operates
  90. 09:12, 23 Apr 2025 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 822 +314 /* A distributor that does not claim manufacture, and what the article may infer from that */ reply
  91. 03:31, 11 Apr 2025 (diff | hist) Sterile water for injection 3,619 ±0 m add the dead-space volume to the worked example
  92. 16:15, 9 Apr 2025 (diff | hist) VendorInvestigate 4,188 ±0 add the note that a purity figure without water and counterion is not a mass
  93. 20:46, 8 Apr 2025 (diff | hist) Karl Fischer titration 7,209 +164 expand §Relationship to other methods
  94. 14:02, 8 Apr 2025 (diff | hist) Talk:Wuhan Wansheng Biotechnology 611 +338 /* RfC: what does a large report set actually support? */ reply
  95. 14:07, 3 Apr 2025 (diff | hist) Talk:Shanghai Wibson Biotechnology 748 +179 /* A shorter registry history is not a finding */ reply
  96. 04:08, 1 Apr 2025 (diff | hist) Chinese Peptide Company 10,512 +526 add the reception tally with its period and count stated
  97. 21:56, 26 Mar 2025 (diff | hist) Deamidation 4,219 +22 expand §Detection
  98. 13:21, 25 Mar 2025 (diff | hist) Talk:Peptide content 748 +234 /* Which convention does a nominal fill follow? */ reply
  99. 09:15, 19 Mar 2025 (diff | hist) Talk:Xi'an Mokemei Biotechnology 537 +298 /* Extract-derived listings need their own treatment */ new section
  100. 09:47, 12 Mar 2025 (diff | hist) Third-party testing 5,770 ±0 m give the fields a compendially-complete certificate would carry